Short answer
HARROW, INC. (HROW) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $72M (up 45.4% year over year) with net income of $1M.
Q3 2025 key financials · XBRL
- Revenue
- $72M
- +45.4% YoY · +12.4% QoQ
- Net income
- $1M
- +124.2% YoY · −79.6% QoQ
- Operating margin
- 20.6%
- Gross margin
- 75.3%
- EPS (diluted)
- $0.03
- +125.0% YoY · −80.0% QoQ
Source: XBRL data from the HARROW, INC. (HROW) Q3 2025 10-Q on SEC EDGAR. USD.
HARROW, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: U.S. government shutdown starting Oct 1, 2025 causing FDA, CMS, SEC staffing cuts, delaying product approvals, reimbursement, and capital access
- Updated legal risk: Ongoing FDA inspections and warning letters (latest May 2023, 2024), with voluntary recalls and remediation raising compliance scrutiny
- Regulatory risk: Inflation Reduction Act enabling Medicare drug price setting, penalties for price increases above inflation, increasing pricing pressure risks
- Operational risk: ImprimisRx facility licensing issues in California risking reduced sales, with potential material impact if other states impose similar restrictions
- Financial risk: Possible supply chain tariffs up to 150% on APIs and components could raise input costs, disrupt supply, and compress gross margins
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HARROW, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.